An anti-VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro.
Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis, where it functions as one of the major angiogenic factors sustaining growth and draining catabolites. In this study, we developed an anti-VEGF ribozyme targeted to the 5' part of human VEGF mRNA. We endowed this ribozyme with an additional feature expected to improve its activity in vivo, by cloning it into a VAI transcriptional cassette. VAI is originally part of the adenovirus genome, and is characterized by high transcription rates, good stability due to its strong secondary structure and cytoplasmic localization. Transfection of U87 human glioblastoma cells with plasmid vectors encoding for this ribozyme resulted in a strong (-56%) reduction of VEGF secreted in the extracellular medium, indicating a good biological activity of the ribozyme. Moreover, this reduction in VEGF secretion had the important functional consequence of drastically diminishing the formation of tube-like structures of human umbilical vascular endothelial cells in a Matrigel in vitro angiogenesis assay. In conclusion, our VAI-embedded anti-VEGF ribozyme is a good inhibitor of angiogenesis in vitro, in a glioblastoma cell context. Thus, it may represent a useful tool for future applications in vivo, for antiangiogenic gene therapy of glioblastoma and of highly vascularized tumors.
Ciafrè
Silvia Anna
SA
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy. ciafre@uniroma2.it
Niola
Francesco
F
Wannenes
Francesca
F
Farace
Maria Giulia
MG
D000260:Adenoviruses, Human / Q000235:genetics*; D001483:Base Sequence / Q000235:genetics; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D008969:Molecular Sequence Data; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D016337:RNA, Catalytic / Q000235:genetics* / Q000378:metabolism*; D012367:RNA, Viral / Q000235:genetics* / Q000378:metabolism; D011995:Recombination, Genetic; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000235:genetics
D016337:RNA, Catalytic; D012367:RNA, Viral; D042461:Vascular Endothelial Growth Factor A; C052835:adenovirus associated RNA